{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(1)"],"submitter":["Shim TS"],"pubmed_abstract":["<h4>Background</h4>Multidrug-resistant tuberculosis (MDR-TB) represents a major public health concern, with an ongoing need for new effective treatments. Bedaquiline is an oral diarylquinoline that has shown encouraging treatment success and culture conversion rates in MDR-TB.<h4>Methods</h4>A South Korean patient registry was set up across 19 centres between 2016 and 2018 for the prospective collection of data from patients with MDR-TB who received either a bedaquiline-containing or a non-bedaquiline-containing regimen. Treatment was at the physician's discretion (bedaquiline use requiring approval by special committee) and was based on patient characteristics, disease status, and local treatment guidelines.<h4>Results</h4>The safety population included 172 patients (88 bedaquiline and 84"],"journal":["BMC infectious diseases"],"pagination":["15"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9828359"],"repository":["biostudies-literature"],"pubmed_title":["A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea."],"pmcid":["PMC9828359"],"pubmed_authors":["Mok J","Park J","Thoret-Bauchet F","Kim H","Lee SH","Mao G","Alquier L","Shim TS","Davis K","Pai H","Kim JH","Bakare N","Kwon YS","Birmingham E","Choi JC"],"additional_accession":[]},"is_claimable":false,"name":"A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea.","description":"<h4>Background</h4>Multidrug-resistant tuberculosis (MDR-TB) represents a major public health concern, with an ongoing need for new effective treatments. Bedaquiline is an oral diarylquinoline that has shown encouraging treatment success and culture conversion rates in MDR-TB.<h4>Methods</h4>A South Korean patient registry was set up across 19 centres between 2016 and 2018 for the prospective collection of data from patients with MDR-TB who received either a bedaquiline-containing or a non-bedaquiline-containing regimen. Treatment was at the physician's discretion (bedaquiline use requiring approval by special committee) and was based on patient characteristics, disease status, and local treatment guidelines.<h4>Results</h4>The safety population included 172 patients (88 bedaquiline and 84","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-06-03T16:49:51.37Z","creation":"2025-04-04T09:30:45.086Z"},"accession":"S-EPMC9828359","cross_references":{"pubmed":["36624432"],"doi":["10.1186/s12879-022-07955-6"]}}